Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus
A Bayesian estimation framework enabled the characterization of empagliflozin PK and PK/PD with a limited number of samples in paediatric patients aged 10-17 years. Overall, the results confirm 10 and 25 mg as the appropriate empagliflozin doses in paediatric patients aged 10-17 years with type 2 diabetes mellitus.
Authors
- Sebastian Härtter
- Cheng Shen (ORCID: https://orcid.org/0000-0002-7493-4784)
- Juliane Rascher (ORCID: https://orcid.org/0009-0009-4131-7104)
- Igor Tartakovsky (ORCID: https://orcid.org/0000-0003-4825-8951)
- Jan Marquard
- Lori M. Laffel (ORCID: https://orcid.org/0000-0002-9675-3001)
- Curtis Johnston
- Wojtyniak Jan‐Georg
Institutions
- Joslin Diabetes Center (US)
- Boehringer Ingelheim (Germany) (DE)
- Harvard University (US)
- Metrum Research Group (United States) (US)
- Boehringer Ingelheim (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1002/bcp.70096
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Eli Lilly and Company